EICHORCondition: Duchenne Muscular Dystrophy · Sponsor: Pfizer
The study will evaluate the safety and efficacy of gene therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study with two thirds of participants assigned to gene therapy. The one third of participants who are randomized to the placebo arm will have an opportunity for treatment with gene therapy at the beginning of the second year.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Arkansas Children's Hospital | Little Rock, Arkansas, United States | — |
| Arkansas Children's | Little Rock, Arkansas, United States | — |
| UCLA Medical Center | Los Angeles, California, United States | — |
| University of Florida | Gainesville, Florida, United States | — |
| University of Iowa Hospitals and Clinics | Iowa City, Iowa, United States | — |
| KU Clinical Research Center - Clinical and Translational Science Unit (CTSU) - Fairway | Fairway, Kansas, United States | — |
| KU Clinical Research Center - Clinical and Translational Science Unit (CTSU) - Rainbow | Kansas City, Kansas, United States | — |
| University of Kansas Hospital - Investigational Pharmacy | Kansas City, Kansas, United States | — |
| University of Kansas Hospital - Pediatric and Pediatric ICU - Operating Room | Kansas City, Kansas, United States | — |
| University of Kansas Medical Center | Kansas City, Kansas, United States | — |
| Pediatric Cardiology | Prairie Village, Kansas, United States | — |
| Lenox Baker Children's Hospital | Durham, North Carolina, United States | — |
+ 41 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04281485